An experimental oral medication known as PLX-4032 is showing the ability to shrink these tumors.
A report in the New England Journal of Medicine finds the targeted therapy was able to shrink tumors in 80 percent of patients in advanced stages of the disease.
Researchers say it's too early to tell if the treatment will improve overall survival rates. But a smaller tumor would likely offer a better quality of life for patients.
